Перейти к основному содержанию
AkademIndex

Продукты

Для разработчиков

AkademBaseОткрытый API экосистемы
Статья

PD-1/PD-L1 in Disease

Nyanbol KuolCentre for Chronic Disease, College of Health & Biomedicine, Victoria University, P.O. Box 14426, MelbourneVIC 8001, AustraliaLily StojanovskaCentre for Chronic Disease, College of Health & Biomedicine, Victoria University, P.O. Box 14426, MelbourneVIC 8001, AustraliaKulmira NurgaliCentre for Chronic Disease, College of Health & Biomedicine, Victoria University, P.O. Box 14426, MelbourneVIC 8001, AustraliaVasso ApostolopoulosCentre for Chronic Disease, College of Health & Biomedicine, Victoria University, P.O. Box 14426, MelbourneVIC 8001, Australia
2017en
ABI

Аннотация

AIM: Expression of PD-1 on T/B cells regulates peripheral tolerance and autoimmunity. Binding of PD-1 to its ligand, PD-L1, leads to protection against self-reactivity. In contrary, tumor cells have evolved immune escape mechanisms whereby overexpression of PD-L1 induces anergy and/or apoptosis of PD-1 positive T cells by interfering with T cell receptor signal transduction. PD-L1 and PD-1 blockade using antibodies are in human clinical trials as an alternative cancer treatment modality. Areas covered: We describe the role of PD-1/PD-L1 in disease in the context of autoimmunity, neurological disorders, stroke and cancer. CONCLUSION: For immunotherapy/vaccines to be successful, the expression of PD-L1/PD-1 on immune cells should be considered, and the combination of checkpoint inhibitors and vaccines may pave the way for successful outcomes to disease.

Перевод пока недоступен

Идентификаторы

Цитирования и источники

Цитирований: 2Использованных источников: 0